2013-01-16 22:32:16 -

Mentor, Ohio (January 16, 2013) - STERIS Corporation (NYSE: STE) today announced
that it will release its fiscal 2013 third quarter financial results before the
market opens on February 6, 2013, followed by a conference call at 10:00 a.m.
Eastern time.  The conference call can be heard live over the Internet at
www.steris-ir.com or via phone by dialing 1- 800-369-8428 in the United States
and Canada, or 1-773-799-3378 internationally, then referencing the password
"STERIS".

For those unable to listen to the conference call live, a replay will be
available beginning at 12:00 p.m. Eastern time on February 6, 2013 either over
the Internet at www.steris-ir.com or via phone by calling 1-800-388-4950 in the
United States and Canada, or 1-203-369-3694 internationally.

About STERIS

The mission of STERIS Corporation is to provide a healthier   today and safer
tomorrow through knowledgeable people and innovative infection prevention,
decontamination and health science technologies, products and services. The
Company has approximately 6,000 dedicated employees around the world working
together to supply a broad array of solutions by offering a combination of
equipment, consumables and services to healthcare, pharmaceutical, industrial
and government Customers. The Company is listed on the New York Stock Exchange
under the symbol STE. For more information, visit www.steris.com.

                                     # # #

The press release and the referenced conference call may contain statements
concerning certain trends, expectations, forecasts, estimates, or other forward-
looking information affecting or relating to the Company or its industry,
products or activities that are intended to qualify for the protections afforded
"forward-looking statements" under the Private Securities Litigation Reform Act
of 1995 and other laws and regulations. Forward-looking statements speak only as
to the date made, and may be identified by the use of forward-looking terms such
as "may," "will," "expects," "believes,"
"anticipates," "plans," "estimates,"
"projects," "targets," "forecasts," "outlook,"
"impact," "potential,"
"confidence," "improve," "optimistic," "deliver,"
"comfortable," "trend", and
"seeks," or the negative of such terms or other variations on such terms or
comparable terminology. Many important factors could cause actual results to
differ materially from those in the forward-looking statements including,
without limitation, disruption of production or supplies, changes in market
conditions, political events, pending or future claims or litigation,
competitive factors, technology advances, actions of regulatory agencies, and
changes in laws, government regulations, labeling or product approvals or the
application or interpretation thereof. Other risk factors are described herein
and in the Company's Form 10-K and other securities filings. Many of these
important factors are outside STERIS's control. No assurances can be provided as
to any result or the timing of any outcome regarding matters described in the
referenced press release or conference call or otherwise with respect to any
regulatory action, administrative proceedings, government investigations,
litigation, warning letters, consent decree, rebate program, transition, cost
reductions, business strategies, earnings or revenue trends or future financial
results (including without limitation the settlement of the SYSTEM 1 class
action litigation and the regulatory matters related to SYSTEM 1E or its
accessories). References to products, the consent decree, the transition or
rebate program, or the class action settlement, are summaries only and should
not be considered the specific terms of the decree, settlement, program or
product clearance or literature. Unless legally required, the Company does not
undertake to update or revise any forward-looking statements even if events make
clear that any projected results, express or implied, will not be realized.
Other potential risks and uncertainties that could cause actual results to
differ materially from those in the forward-looking statements include, without
limitation, (a) the potential for increased pressure on pricing or costs that
leads to erosion of profit margins, (b) the possibility that market demand will
not develop for new technologies, products or applications or the Company's
rebate program, transition plan or other business initiatives will take longer,
cost more or produce lower benefits than anticipated, (c) the possibility that
application of or compliance with laws, court rulings, certifications,
regulations, regulatory actions, including without limitation those relating to
FDA warning notices or letters, government investigations, the April 20, 2010
consent decree and related transition plan and rebate program, the SYSTEM 1E
device, the outcome of any pending FDA requests, inspections or submissions, or
other requirements or standards may delay, limit or prevent new product
introductions, affect the production and marketing of existing products or
services or otherwise affect Company performance, results, prospects or value,
(d) the potential of international unrest, economic downturn or effects of
currencies, tax assessments, adjustments, or anticipated rates, raw material
costs or availability, benefit or retirement plan costs, or other regulatory
compliance costs, (e) the possibility of reduced demand, or reductions in the
rate of growth in demand, for the Company's products and services, (f) the
possibility that anticipated growth, cost savings, rebate assumptions, new
product acceptance, performance or approvals, including without limitation
SYSTEM 1E and accessories thereto, or other results may not be achieved, or that
transition, labor, competition, timing, execution, regulatory, governmental, or
other issues or risks associated with our business, industry or initiatives
including, without limitation, the consent decree, rebate program, and the
transition from the SYSTEM 1 processing system and adjustments to related
reserves, or those matters described in our Form 10-K for the year ended
March 31, 2012 and other securities filings, may adversely impact company
performance, results, prospects or value, (g) the possibility that anticipated
financial results or benefits of recent acquisitions will not be realized or
will be other than anticipated, (h) the effect of the contraction in credit
availability, as well as the ability of our Customers and suppliers to
adequately access the credit markets when needed, and (i) those risks described
in our securities filings including our Annual Report on Form 10-K for the year
ended March 31, 2012, and other securities filings.

Contact: Julie Winter, Director, Investor Relations at 440-392-7245.




This announcement is distributed by Thomson Reuters on behalf of 
Thomson Reuters clients. The owner of this announcement warrants that: 
(i) the releases contained herein are protected by copyright and 
    other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and 
     originality of the information contained therein. 
    
Source: Steris Corporation via Thomson Reuters ONE
[HUG#1671041]